Status:
COMPLETED
Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion
Lead Sponsor:
Ain Shams University
Conditions:
Gram-Negative Infections
Eligibility:
All Genders
18-74 years
Phase:
PHASE4
Brief Summary
Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent dosage regimen has shown observable outcomes. Our objective is to assess whether continuous infusion of pipe...
Detailed Description
A total of 56 patients were recruited from ICU- Cairo University Hospitals. All adult critically ill patients admitted to Critical Care Medicine Department with suspected or confirmed bacterial infect...
Eligibility Criteria
Inclusion
- Adults aged 18-74 years
- Expected ICU stay more than 24 hours
Exclusion
- Allergy or potential allergy to the study medications
- Pregnancy
- Patients with CrCl\< 20 ml/min or on dialysis
- Cancer patients
Key Trial Info
Start Date :
July 27 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 26 2020
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04895657
Start Date
July 27 2018
End Date
January 26 2020
Last Update
May 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University Hospitals
Cairo, Egypt